Friday, 16 October 2026European Markets

ALMUNDA PRO NV Stock Is 20% Up So Far On Wednesday

Loading stream...

(VIANEWS) - Shares of ALMUNDA PRO NV (AEX-Index: AMUND.AS) jumped by a staggering 20.3% to €1.60 at 11:06 EST on Wednesday, after two sequential sessions in a row of losses. AEX-Index is dropping 1.39% to €755.36, following the last session's downward trend. This seems, at the moment, an all-around down trend exchanging session today.

ALMUNDA PRO NV's last close was €1.33, 14.19% under its 52-week high of €1.55.

About ALMUNDA PRO NV

Almunda Professionals N.V., a business and IT consultancy company, provides business services in the financial sector. It offers consultancy services in the areas of regulatory change, digital transformation, information security, and information services. The company was formerly known as Novisource N.V. and changed its name to Almunda Professionals N.V. in August 2021. Almunda Professionals N.V. was founded in 2001 and is based in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, ALMUNDA PRO NV has a trailing twelve months EPS of €0.02.

PE Ratio

ALMUNDA PRO NV has a trailing twelve months price to earnings ratio of 80. Meaning, the purchaser of the share is investing €80 for every euro of annual earnings.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Jun 23, 2022, the estimated forward annual dividend rate is 0.05 and the estimated forward annual dividend yield is 3.73%.

Volatility

ALMUNDA PRO NV's last week, last month's, and last quarter's current intraday variation average was a negative 0.42%, a positive 0.18%, and a positive 5.45%.

ALMUNDA PRO NV's highest amplitude of average volatility was 10.12% (last week), 5.65% (last month), and 5.45% (last quarter).

Yearly Top and Bottom Value

ALMUNDA PRO NV's stock is valued at €1.60 at 11:06 EST, higher than its 52-week high of €1.55.

Moving Average

ALMUNDA PRO NV's worth is way higher than its 50-day moving average of €1.32 and way higher than its 200-day moving average of €1.29.

More news about ALMUNDA PRO NV (AMUND.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com